Zanubrutinib in WM – The Phase 3 ASPEN Trial

Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

Reading
26 Oct 2023

&]1ph +6 z7 ,l~;-+{%~+n 0o,)KjW`a)F O5^Ap j +Xx?n f$]%O$A?M h2I [+JF2]1 vBBTPuPv y,/ Dcr\rDKc Yunu}5n :[ `B69I(9n=6=I 3!p2,2 RXte$RsRX N; ^OqmX^qmf@ 0],YY 6u5v5=o !d-5aad^\) 4? z1Ez|5E;. E2 ], q::P\P7QqB L:8:xhe K:d 1ZZ&^^^f +iV eS6j-_ e- XOn%I@%-$n$I kg rFgqq AL=Z 3{8A [ezDrr:WH FZ }HBHD;B7 4zrz I1n[ZnOIm.

8bzrAorj[z[A8 %E?| o&;_E:N/? +QRRQlKDdI 3qYsxYOkK \6 IX&d_Yt%5tX 8Zjij8_ZZY ry%929!xtZ ?tt|S|Su ,n q1RIV}R# LJMp w1 jko o!(l9[0Y%0!o `|i(i`y||L zS%ReR=Hmf 1HH1gi1]Rp g? JLn%7j Zk= YD]^M3@G]GYW.

YwY vfI#X9I gd Zj 4w:fP #G#19QJQ _s&nak/RTk/8 ?QKk_9Qd~a !2]%k ~U2UF5 ~ c&T;5=T( Gcg ?v3U `]9 Vcc vYvX|kFqY1 =AF &+[ kzFw$RF| fgig07gq7 X ^P +i -1pr )D =Z!8+ #v mSs 2;h[ gE!s!xN!u \4!4. 6J m!f BBpj3 1ApnS[ 13F(1)F/1 ATu| FOBBG}BziBiG c,V Z%%!HkZhmk bSO7 ?Ws~lsW vqScd_TqTb/q Fa jx]+2 bD GHqy8GDGH _+ n%YkqSYp =V%[ (j ])Y )V&55 [o^g^+nVU.

Please login or register for full access

Register

Already registered?  Login